Biodesix, Inc.

BDSX

CIK 0001439725 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$29M
↑+40.8% +$8Mvs FY2024 (Q4)
Operating Income
$2M
Gross Profit
$29M
↑+40.8% +$8Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Strong
71/100
  • Profitability
    0ROIC -40.6% (10% = solid, 20%+ = moat)
  • Liquidity
    68Current Ratio 1.86 (above 1.5 = solid)
  • Leverage
    100D/E -20.29 (under 0.5 = conservative)
  • Efficiency
    58Asset Turnover 0.96x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +40.8% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -32.4% · trend +11.9pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$259K
investment in PP&E
Stock-based comp (TTM)
$4M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$87M
everything owned
Total liabilities
$90M
everything owed
Stockholders' equity
$-2M
shareholder claim
Net debt
$31M
LT debt minus cash

Recent performance · 28 quarters

Revenue↑+40.8% +$8M
$29M
Net Income↑+15.0% +$2M
$-9M
Free Cash Flow↑+182.5% +$2M
$692K
Operating Margin↑+14.9pts
-32.4%

Drill down